The Chinese character “ren” means people and humanity.
RenBio was founded on the principle that the remarkable medical benefits of antibody therapeutics should be available to everyone.
Advance first-in-class and best-in-class DNA therapeutic technologies to humans.
Modernize and transform the antibody and therapeutic protein fields to significantly reduce the impact of diseases worldwide.
Deliver antiviral antibodies to prevent the spread of infectious diseases and improve the dosing regimen and effectiveness of therapeutic proteins.
Using RenBio’s Make Your Own (MYO) Technology, therapeutic-encoding “bioblueprints” are delivered via modified intramuscular injection, which are then decoded by the muscle cells to produce disease-fighting therapeutics in the patient’s own body.
Antibody and protein therapeutics can provide an overwhelming benefit for human health, but major obstacles in their administration, efficacy, durability, and cost limit their more widespread use. We have reimagined the way antibody and protein therapeutics can be produced and delivered to overcome these obstacles.
Our delivery platform takes advantage of the body’s ability to produce any given antibody or therapeutic protein when provided with the precise set of genetic instructions. These instructions, encoded in DNA, are biological blueprints.
RenBio was co-founded by Drs. David Ho and Yaoxing Huang, visionary scientists affiliated with the Aaron Diamond AIDS Research Center in New York City. Since opening our doors in 2016, we have rapidly grown into a diverse, multidisciplinary team, with expertise spanning a range of biological and engineering fields. Our approach leverages the breadth of our collective knowledge to develop a true platform technology with the ability to deliver antibodies and therapeutic proteins for the prevention and treatment of multiple diseases.